These are pathogen-derived nonenzyme proteins that exploit the ‘molecular sexual-ity’ in the activation mechanism of plasminogen and Keywords coagulation; conformation; fibrinolysis; pla
Trang 1Small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems
Keiji Hasumi, Shingo Yamamichi and Tomotaka Harada
Department of Applied Biological Science, Tokyo Noko University, Japan
Introduction
The coagulation and fibrinolytic systems are central
to the hemostatic mechanism This mechanism is
pri-marily responsible for preventing blood leakage and
secondarily for tissue repair and wound healing
Interactions between a variety of enzymes and
nonen-zyme components account for the finely regulated
pro-cesses in the coagulation and fibrinolytic systems [1,2]
Most of the enzymes in these systems are serine
prote-ases circulating as either inactive proenzyme or
proen-zyme forms with very low activity Thus, their
activation is a prerequisite for their function, whereas
their inhibition or inactivation is also important in the
regulation and termination of the reaction Activation
of the zymogens is a consequence of a conformational
change triggered by specific proteolytic cleavage(s) of
the zymogen [3,4] The activated enzyme catalyzes the
subsequent step or upstream reaction(s) in the cascade
to amplify and⁄ or regulate the systems The reactions
in both systems operate instantly after exposure to pathophysiological stimuli Therefore, the mechanism
of their regulation is programmed in the structure of each component of the systems, and modulation of the programmed function of the component can provide a novel means of pharmacological intervention in dis-eases associated with the coagulation and fibrinolytic systems Most extensively studied examples of zymo-gen modulation are nonproteolytic conformational activations of plasminogen by streptokinase, and pro-thrombin by staphylocoagulase (and von Willebrand factor-binding protein) These are pathogen-derived nonenzyme proteins that exploit the ‘molecular sexual-ity’ in the activation mechanism of plasminogen and
Keywords
coagulation; conformation; fibrinolysis;
plasma hyaluronan-binding protein;
plasminogen; plasminogen activator;
protease; prothrombin; urokinase; zymogen
activation
Correspondence
K Hasumi, Department of Applied Biological
Science, Tokyo Noko University,
3-5-8 Saiwaicho, Fuchu-shi,
Tokyo 183-8509, Japan
Fax: +81 42 367 5708
Tel: +81 42 367 5710
E-mail: hasumi@cc.tuat.ac.jp
(Received 29 April 2010, revised 8 July
2010, accepted 19 July 2010)
doi:10.1111/j.1742-4658.2010.07783.x
The coagulation and fibrinolytic systems are central to the hemostatic mechanism, which works promptly on vascular injury and tissue damage The rapid response is generated by specific molecular interactions between components in these systems Thus, the regulation mechanism of the sys-tems is programmed in each component, as exemplified by the elegant pro-cesses in zymogen activation This review describes recently identified small molecules that modulate the activation of zymogens in the fibrinolytic and coagulation systems
Abbreviations
AH site, aminohexyl site; EGF, epidermal growth factor; Lp(a), lipoprotein(a); PA, plasminogen activator; PAN domain,
plasminogen ⁄ apple ⁄ nematode domain; PHBP, plasma hyaluronan-binding protein; scu-PA, single-chain urokinase-type plasminogen activator; SMTP, Stachybotrys microspora triprenyl phenol; tcu-PA, two-chain urokinase-type plasminogen activator; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator.
Trang 2prothrombin (insertion of N-terminal Ile or Val into
N-terminal binding cleft of the catalytic domain,
resulting in conformational activation of the substrate
binding site and oxyanion hole required for proteolytic
activity) [5–8]
Our laboratory has been searching for
small-mole-cule natural products that enhance the fibrinolytic
system We initially aimed at identifying a candidate
small molecule that could contribute to the treatment
of thrombotic and embolic complications As a result,
we have identified several types of compounds,
includ-ing modulators of zymogen activations Detailed
anal-yses of the action of such modulators have expanded the concept of zymogen modulation, leading to the identification of additional modulators that affect the coagulation system The active compounds and their targets are summarized in Table 1 and Fig 1 Here,
we review the identification and functional character-ization of such small-molecule modulators of zymogen activation in the fibrinolytic and coagulation systems
Plasminogen modulator
The plasminogen⁄ plasmin system The plasminogen⁄ plasmin system plays a central role
in blood clot lysis [2,9] This system is also important
in other pathophysiological events in which localized proteolysis is involved [10–12] The circulating form
of plasminogen (Glu-plasminogen) is a single-chain zymogen consisting of 791 amino acids, which form the following domain structures: a plasminogen⁄ apple⁄ nematode (PAN) domain, five kringle domains and a serine protease domain (Fig 2) [13,14] It is proteolytically activated to plasmin by plasminogen activators (PAs) through specific cleavage at Arg561– Val562 Urokinase-type and tissue-type PAs (u-PA and t-PA, respectively) are major physiological activators
Table 1 Small-molecule zymogen modulators identified in this
labo-ratory PHBP, plasma hyaluronan-binding protein; scu-PA,
single-chain urokinase-type plasminogen activator; SMTP, Stachybotrys
microspora triprenyl phenol.
Plasminogen Complestatin and chloropeptin I [43,44,52]
Staplabin and SMTPs [45–53]
scu-PA ⁄ plasminogen
reciprocal activation
Surfactins and iturins [68,69]
Glucosyldiacylglycerol [70]
Pro-PHBP Polyamines and carminic acid [104]
OH
H O
N
H
HOOC
OH
O
N H O
O
O N
O O
OH Cl
Cl
OH
HN O
OH Cl
HOOC N
H N H
O S NH
NH S
NH
S NH
O NH R
NH OH
CH 2 O
CH 2 O
CH 2 O
CH 2 O N
N
CH 2
O
CH2 O N
O N O N
O
O N
N O R O
OH HO
O
CH 3
COOH OH OH
HO
O HO
OH
OH OH
O
HO
O
HN
N NH NH NH H HN
O
O
O
O O
O
O OH
Glu
Leu
D-Leu
Leu
Val
Asp
D-Leu
NH
NH2 HN
NH N HN O
O O O
O
D-Leu
Phe
Leu
HN
NH H
O
O O
O O
S S D-Cys
D-Cys
Val
Ile
D-Leu
O
H HO
CHO CHO
O
HO OH OH
OR 2
OR 1
Complestatin
Thioplabins
Staplabin/SMTPs
Stachybotrydial
Glucosyldiacylglycerol
Surfactin C Plactin D Malformin A1 Carminic acid
HO
Fig 1 Structures of the modulators of zymogen activation R in the thioplabin structure corresponds to –CH3, –CH2CH3or –CH(CH3)2for thioplabin A, B or C, respectively R in the structure of SMTPs represents one of a variety of substituents, most of which are derived from amino acids R1and R2in the structure of glucosyldiacylglycerol correspond to the oleoyl or palmitoyl group Malformin A1, which enhances cellular fibrinolytic activity through a mechanism distinct from direct modulation of zymogen activation, is shown to compare its structure with that of plactin D.
Trang 3[2] Glu-plasminogen adopts a closed conformation
because of the intramolecular binding of Lys50 and⁄ or
Lys62 to the fifth kringle domain (K5) (Fig 3) [15,16]
The tight conformation renders Glu-plasminogen
less sensitive to activation by PAs [17,18] The
Glu-plasminogen binding to fibrin or cellular receptors
allows relaxation of Glu-plasminogen conformation,
enabling efficient activation (Fig 3) This mechanism
facilitates localized activation of plasminogen and
extracellular proteolysis [19,20] Growing evidence
sup-ports the idea that cellular plasminogen binding plays
roles in physiological processes such as macrophage
recruiting, leukocyte migration and liver regeneration
[21–24]
During the course of fibrinolysis, Lys-plasminogen
(Fig 2), a truncated form of Glu-plasminogen,
pre-dominantly with an N-terminal Lys78, appears
through autoproteolysis by the resulting plasmin
[25,26] The molecule no longer has the PAN domain
and therefore adopts a relaxed conformation [27] because of the lack of intermolecular binding between the PAN domain and K5 (Fig 3) Lys-plasminogen is highly sensitive to activation even in the absence of fibrin or cells
PAN–K5 binding is mediated via the aminohexyl (AH) site in K5 [28,29] (Fig 3) Unlike lysine-binding sites in K1, K2 and K4 of plasminogen, the AH site can bind an internal lysine residue in addition to the C-terminal lysine [30], which is a preferred ligand for the lysine-binding site in K1, K2 and K4 Thus, amin-ohexyl or lysine analogs can interfere with PAN–K5 binding and relax Glu-plasminogen conformation, ren-dering Glu-plasminogen susceptible to activation by PAs [31,32] Some proteins, as well as cell-surface plas-minogen receptors, interact with kringles and modulate plasminogen activation [33,34] It is postulated that the fibrinolytic process proceeds as follows [35]: at an ini-tial phase, the K5–fibrin interaction accumulates Glu-plasminogen on fibrin Subsequently, partially degraded fibrin, which has C-terminal lysines, plays a role in fibrinolytic propagation by serving as more effi-cient binding sites for plasminogen The high-affinity lysine-binding sites in K1 and K4 may be involved in this propagation process Thus, plasminogen binding is essential for the fibrinolytic process The kringle ligands, however, inhibit plasminogen binding to fibrin and cellular receptors and, therefore, suppress fibrino-lysis This is the basis of the antihemorrhagic action of lysine analogs such as tranexamic acid and 6-amino-hexanoic acid [36]
Competition in the binding between plasminogen and fibrin or cellular receptors can occur via physio-logic molecules Lipoprotein(a) [Lp(a)], a risk factor for coronary heart disease [37,38], is a plasma lipopro-tein related to low-density lipoprolipopro-tein In the Lp(a) molecule, apolipoprotein B-100, which is a sole protein component of low-density lipoprotein, is covalently modified with apolipoprotein(a), a protein closely related to plasminogen, consisting of multiple (11–50 repeats) K4-like domains, a K5-like domain and a pseudo-protease domain [39,40] Lp(a) can compete with plasminogen for binding to fibrin or cell-surface receptors and attenuate localized plasminogen activa-tion [41] and conversion of Glu-plasminogen to Lys-plasminogen [42] These findings suggest a possible link between thrombosis and atherosclerosis
Our laboratory has screened up to 10 000 microbial cultures for their ability to enhance Glu-plasminogen binding to fibrin or culture cells This attempt is based
on the hypothesis that relieving the plasminogen bind-ing competition might enhance fibrinolytic activity The active compounds identified include complestatin
Gla K1
P
R I
T 285 321 320
K
E K I P
S 1
A 1
F 1
F 1
S 1
159 158
K4 K1 K2 K3 K5 P
E 1
K 78
K 78
K4 K1 K2 K3 K5 P
R
K4 K1 K2 K3 K5 V P
562
E1 E2 E3 K P
R
E1 E2 E3 K I P
291 290
PAN
Prothrombin
α-Thrombin
Glu-plasminogen
Pro-PHBP
PHBP
Lys-plasminogen
Plasmin
scu-PA
tcu-PA
561
Fig 2 Structures of key zymogens and their active forms Each
molecule is shown schematically with each domain in a colored
circle The disulfide bond that connects the A- and B-chains of the
mature protease is shown in green Red lines in the PHBP
molecule represent the N-terminal region (NTR) PAN, PAN domain;
K, kringle domain; P, protease domain; Gla, c-carboxyglutamic acid
domain; E, EGF domain.
Trang 4[43] and its isomer chloropeptin I [44], staplabin [45]
and its congener Stachybotrys microspora triprenyl
phenols (SMTPs) [46–53], thioplabins [54] and
stachyb-otrydial [55]
Complestatin and chloropeptin I
Tachikawa et al [43] isolated complestatin, a
chlorine-containing peptide metabolite from Streptomyces sp.,
as an active principle that enhanced Glu-plasminogen
binding to cultured U937 monocytoid cells
Complest-atin enhances the binding by several fold at 1–10 lm
The enhancement is observed in either the absence or
presence of Lp(a) The compound is also effective in
elevating Glu-plasminogen–fibrin binding The actions
of complestatin are canceled by a lysine analog Thus,
the target of complestatin is Glu-plasminogen, and the
agent promotes its binding to fibrin and cells via the
AH site or the lysine-binding sites However, the initial
characterization does not clarify the exact mechanism
of the complestatin actions The current understanding
is that the action of complestatin modulates
Glu-plas-minogen conformation [52], but verification of this has
awaited the characterization of staplabin and SMTPs
However, the concept that small molecule-mediated
augmentation of plasminogen binding results in
increased plasmin formation on cell surfaces has been
confirmed by experiments using complestatin [43]
Chloropeptin I, an isomer of complestatin, has a
similar but slightly different effect on plasminogen
binding compared with complestatin [44]
Chloropep-tin I is 3–10 times more active than complestaChloropep-tin in
enhancing cellular binding of Glu-plasminogen,
cell-surface plasmin formation, and whole-blood
fibrinolysis assessed by thromboelastography, although the agent is less active in promoting fibrin binding of Glu-plasminogen Although the structural difference between complestatin and chloropeptin I is only at the position of the C–C bond that connects the indole ring
of the tryptophan residue and the aromatic ring of the 3,4-dihydroxyphenylglycine residue, a large difference
in conformation between the two compounds is evident from the nuclear Overhauser effect in NMR spectroscopy It is speculated that this difference may account for the distinct activities of the two compounds [44]
Staplabin and SMTP Shinohara et al [45] discovered a novel triprenyl phe-nol compound, named staplabin, from a culture of the fungus Stachybotrys microspora, as an active principle that enhanced Glu-plasminogen binding to fibrin Later, several new staplabin congeners, SMTPs, were isolated by Kohyama et al [46], Hasumi et al [48,53], and Hu et al [49,51] These are named after Stachybot-rys microspora triprenyl phenol The staplabin⁄ SMTP molecule consists of a tricyclic c-lactam moiety, an iso-prene side chain and an N-linked side chain (Fig 1) Most of the congeners differ in the N-linked side chain moiety, which is essential for their activity The N-linked side chain can be derived from an amine present in the culture medium, and this finding enabled selective, efficient production of SMTP congeners through an amine-feeding cultivation of S microspora [50,51,53]
Staplabin enhances Glu-plasminogen binding to both fibrin and cultured U937 cells [45] These
K4 K2
K5 P
Fibrin or cellular receptor
PA
K 78
K 78
K4
K1
P
R 561
V 562
Glu-plasminogen
(Closed conformation)
Plasmin
(Open conformation)
K4 K2
K5
P K1
Lys-plasminogen
(Open conformation)
E 1
E 1
P K3 K2 K1
K5 K4 K PAN
50
PAN
D55 D57 W62
W64
F36
Y72
I35 L71 H33 H31
K5 structure
K3
K2 K3 K5
K1
K3
Fig 3 A model of the conformational regulation of plasminogen activation The plasminogen and plasmin molecules are shown as in Fig 2 The schematic conformation shown is speculative, because detailed experimental data are not yet available Key disulfide bonds are shown
in green The molecular structure K5 is shown in the right-hand box The electrostatic surface image, in which areas of neutral, negativeand positive potential are depicted in white, red and blue, respectively, was constructed using the coordinate deposited in the RCSB Protein Data Bank with the code number 2KNF The labeled amino acids are those implicated in the binding of the lysine analog tranexamic acid [29].
Trang 5bindings are mediated by the lysine-binding site or the
AH site, because a lysine analog inhibits the bindings
These activities are quite similar to those of
complesta-tin and chloropepcomplesta-tin I Takayasu et al [47] show that
staplabin promotes PA-dependent Glu-plasminogen
activation The two staplabin activities, the elevation
of Glu-plasminogen-fibrin binding and the promotion
of Glu-plasminogen activation, are observed at the
same range of staplabin concentrations Thus, a
com-mon mechanism may govern the two effects The fact
that the activation of Glu-plasminogen is a
conforma-tionally regulated process is the key to understanding
this mechanism The effect of staplabin on the
activa-tion of Lys-plasminogen, which adopts an open
con-formation, is less prominent than its effect on
Glu-plasminogen Similarly, smaller effects of staplabin on
Glu-plasminogen activation are observed in the
pres-ence of the lysine analog 6-aminohexanoic acid or
fibrinogen fragments, both of which relax
Glu-plasmin-ogen conformation The molecular elution time of
both Glu-plasminogen and Lys-plasminogen is slightly
but significantly shortened in the presence of staplabin
These results support the idea that the staplabin effects
are related to the conformational status of
plasmino-gen, and Takayasu et al [47] have concluded that
staplabin modulates plasminogen conformation,
rendering the molecule susceptible to proteolytic
acti-vation and to binding to cells and fibrin The reason
why the effects of staplabin on Glu-plasminogen is
lar-ger than its effect on Lys-plasminogen can be
explained by the fact that the impact of the
conforma-tional effect depends on the initial conformaconforma-tional
status of plasminogen With respect to the
conforma-tional modulation that leads to an elevated
Glu-plasminogen activation, the staplabin effect is similar
to that of lysine analogs, whereas the effects of each
compound on plasminogen binding are quite different
This implies that staplabin acts as a plasminogen
modulator that works through a mechanism distinct
from the lysine-binding site (or AH site) occupancy
Staplabin congener SMTPs may act on plasminogen
activation and binding similarly to staplabin, whereas
some congeners, such as SMTP-7 and -8, are far more
potent than staplabin [49] The action of
stapla-bin⁄ SMTP is shown schematically in Fig 4
Pharma-cological evaluations of SMTP-7 suggest that the
compound is a promising candidate drug for treating
thrombotic and embolic complications Detailed
inves-tigations are now under way
Plasmin formation in the presence of SMTP is
tran-sient in an incubation of Glu-plasminogen with u-PA
[52] A decrease in plasmin activity follows a rapid
increase in plasmin formation This is because of
auto-proteolytic degradations of the catalytic domain of the plasmin molecule Ohyama et al speculate that the conformational change brought about by SMTP affects susceptibility to autoproteolytic cleavage 6-Aminohexa-noic acid does not lead to autoproteolysis, but enhances plasminogen activation Thus, the difference between conformational modulation by SMTP and that by the lysine analog is also evident from these results Similar promotion of plasmin autoproteolysis is observed with complestatin [52] This effect is obtained with a concen-tration range identical to that effective in enhancing Glu-plasminogen binding, suggesting complestatin’s action as a plasminogen modulator As expected, com-plestatin-mediated enhancement of Glu-plasminogen activation has been confirmed
Thioplabins Ohyama et al [54] identified thioplabins (or antibiotic A10255) (Fig 1), a family of thiopeptide metabolites from Streptomyces sp., as modulators of plasminogen binding Thioplabin B enhances the binding of both Glu-plasminogen and Lys-plasminogen to fibrin It also promotes PA-dependent activation of Glu- and Lys-plasminogen Like staplabin, the effect of thiopla-bin B is smaller on conformationally relaxed Lys-plas-minogen Thioplabin B alters patterns of proteolytic degradation of Glu- and Lys-plasminogen upon
E 1
K4
E 1
Fibrin or cellular receptor
Glu-plasminogen
(Conformational change)
Modulator
PAN
P
K2 K1
K5 K4 K3
K 50
K2 K3
K4
K1
P K5 R 561
V 562
Plasmin
PA
K2 K3
E 1
PAN
P
K3 K2 K1
K5
50
K5
Fig 4 A model of the action of the plasminogen modulator stapla-bin ⁄ SMTP Staplabin and SMTP alter plasminogen conformation and enhance both PA-dependent plasminogen activation and bind-ing to fibrin or cellular receptors Although these compounds can also modulate the functions of Lys-plasminogen, the magnitude of the effects is small, possibly because Lys-plasminogen adopts a more relaxed conformation compared with Glu-plasminogen The schematic model shows only the modulation of Glu-plasminogen function.
Trang 6incubation with elastase The agent also increases
auto-proteolytic degradation of the plasmin catalytic
domain [52] These features conform to the concept of
the nonlysine-analog plasminogen modulator
estab-lished by staplabin⁄ SMTP Thioplabin analogs that
lack the terminal carboxyl group are inactive in
plasminogen modulation [54]
Stachybotrydial
Stachybotrydial (Fig 1) is a tripreny phenol metabolite
from Stachybotrys sp., structurally distinct from
staple-bin⁄ SMTPs Sasaoka et al [55] show that
stachybotry-dial has a specific effect on Glu-plasminogen It
enhances the activation and fibrin binding of
Glu-plas-minogen, but not Lys-plasminogen Unlike the
modu-lation of plasminogen function by other small
molecules described above, the action of
stachybotry-dial involves covalent modification of
Glu-plasmino-gen Because covalent stachybotrydial modification is
observed even with Lys-plasminogen, the selective
effects on Glu-plasminogen are related to its
confor-mational status Thus, stachbotrydial represents
another class of plasminogen modulators in addition
to complestatin⁄ chloropeptin I, staplabin ⁄ SMTP and
thiplabins, which reversibly modulate the function of
Glu- and Lys-plasminogen
Modulator of the reciprocal activation
of single-chain u-PA and plasminogen
Reciprocal activation of single-chain u-PA and
plasminogen
Of the two major physiological plasminogen activators,
t-PA is postulated to play a role in fibrin dissolution in
the circulation, whereas u-PA is involved in pericellular
proteolysis [2] t-PA has a significant affinity for fibrin
and exhibits activity more than two orders of magnitude
higher in the presence of fibrin through the formation of
a cyclic ternary complex with plasminogen and fibrin
[56,57] u-PA, which consists of an epidermal growth
fac-tor (EGF) domain, a kringle domain (which does not
contain a lysine-binding site) and a protease domain
(Fig 2), has little affinity to fibrin and utilizes a distinct
mechanism to regulate localized proteolysis u-PA is
syn-thesized as a single-chain zymogen (scu-PA), and binds
to the cell-surface receptor u-PAR via its EGF domain
[58,59] in an autocline manner to facilitate the activation
of cell-bound plasminogen for pericellular proteolysis
involved in a variety of conditions including tissue
remodeling, macrophage function, ovulation and tumor
invasion [60,61] scu-PA is specifically cleaved at Lys158–
Ile159 by plasmin, affording a two-chain derivative (Fig 2) that has a full protease activity [62] Thus, the reciprocal activation of scu-PA and plasminogen constitutes a mechanism of localized initiation and propagation of pericellular proteolysis [63–66] and fibri-nolysis on platelets [67] The mechanism of the initiation
of the reaction (how the two zymogens activate each other in the initial phase), however, remains to be fully elucidated
A screen of natural sources, including microbial cul-tures and plant extracts, for a modulator of the recipro-cal activation system has led to the identification of surfactins [68], iturins Cs [69] and glucosyldiacylglycerol [70]
Surfactins and iturins Surfactin C (Fig 1), a cyclic heptapeptide with a fatty acid ester in the cyclic structure, is a metabolite from Bacillussp Kikuchi and Hasumi [68] show that surfac-tin C modulates the reciprocal activation of Glu-plasminogen and scu-PA Upon incubation with Glu-plasminogen and scu-PA, the spontaneous activa-tion of both Glu-plasminogen and scu-PA proceeds slowly Surfactin C markedly enhances the concomi-tant formation of tcu-PA and plasmin The surfactin C action involves modulation of Glu-plasminogen activa-tion through relaxing the conformaactiva-tion of the protein Surfactin C increases the intrinsic fluorescence of Glu-plasminogen, shortens molecular elution time in size-exclusion chromatography, and enhances fibrin-binding and activation of Glu-plasminogen catalyzed
by tcu-PA or t-PA [68] Thus, surfactin C can be a plasminogen modulator, but the mechanism by which the agent promotes the initiation of the reciprocal acti-vation is not fully understood A possible explanation would be that the modulation of Glu-plasminogen con-formation allows cleavage by scu-PA, which has very low intrinsic activity toward native Glu-plasminogen (< 0.4% of tcu-PA [71]) Surfactin C, in combination with scu-PA, significantly enhances thrombolysis in a rat pulmonary embolism model [68]
Surfactin C belongs to a large family of lipopeptides that includes surfactins (heptapeptides consisting of two acidic and five aliphatic amino acids), iturin As (heptapeptide consisting of six polar amino acids and
a proline) and iturin Cs (heptapeptide consisting of five polar and an acidic amino acids as well as a proline) All the surfactins and iturin As tested are effective in enhancing the reciprocal activation and tcu-PA-catalyzed Glu-plasminogen activation, whereas iturin Cs, which contain no carboxyl group, are inac-tive [69]
Trang 7Wu et al [70] identified glucosyldiacylglycerol (Fig 1),
a cellular constituent of the seaweed Sargassum
fulvel-lum, as a stimulator of the reciprocal activation of
scu-PA and Glu-plasminogen The apparent action of
glucosyldiacylglycerol is similar to that of surfactin C
in that it leads to the mutual activation of scu-PA and
Glu-plasminogen Unlike surfactin C, however,
gluco-syldiacylglycerol minimally affects Glu-plasminogen
activation catalyzed by tcu-PA and t-PA Thus, the
agent likely represents a different class of zymogen
modulator than the plasminogen modulators
Gluco-syldiacylglycerol markedly enhances scu-PA-mediated
Glu-plasminogen activation in the absence of the
con-version of scu-PA to tcu-PA Upon incubation with
glucosyldiacylglycerol, the intrinsic fluorescence of
scu-PA, but not tcu-PA or Glu-plasminogen, increases
significantly Thus, glucosyldiacylglycerol may act on
scu-PA to draw intrinsic PA activity in the zymogen
The agent enhances fibrin dissolution mediated by
scu-PA and Glu-plasminogen
Modulator of the activation of
prothrombin
Prothrombin activation
The formation of thrombin from its zymogen
prothrom-bin is the central event in the coagulation cascade In
addition to the conversion of fibrinogen to fibrin,
thrombin orchestrates the coagulation and fibrinolytic
processes through activation of factors V, VIII, XI and
XIII [1], as well as protein C [72] and
thrombin-activat-able fibrinolysis inhibitor [73] after binding to
thrombo-modulin In addition, thrombin triggers a variety of
cellular responses by binding to and specifically cleaving
the extracellular domain of the family of
G-protein-cou-pled receptors, protease-activated receptors [74]
Pro-thrombin, a 579-amino-acid glycoprotein, consists of a
c-carboxyglutamic acid domain, two kringle domains
and a protease domain (Fig 2) [75] Prothrombin
acti-vation is due to proteolytic cleavage at Arg320–Ile321,
followed by cleavage at Arg271–Thr272 [76–78] An
additional cleavage at Arg284–Thr285 by thrombin
itself affords mature a-thrombin At the site of vascular
injury, prothrombin is rapidly activated to thrombin by
the coagulation factor Xa which is Ca2+-dependently
assembled with factor Va on acidic phospholipid
mem-branes of damaged vascular endothelium or activated
platelet aggregates [76,79–82] Activation of
prothrom-bin by the complex (prothromprothrom-binase complex) is
more than 105 times faster than that by free Xa [83]
Therefore, physiological coagulation is essentially cata-lyzed by the prothrombinase complex
Dual modulation of prothrombin activation by plactin
Inoue et al [84] discovered a family of novel cyclic pentapeptides after screening microbial cultures for agents that enhanced cellular fibrinolytic activity in an incubation of U937 cells with plasma The cyclopenta-peptides, designated plactins, consist of an aromatic (Phe or Tyr), a basic (d-Arg) and three bulky aliphatic amino acids (d-Val, Leu and d-Leu or d-allo-Ile) (see Fig 1 for the structure of plactin D) The structure– activity relationships of 50 synthetic plactins demon-strate that a sterically restricted arrangement of four hydrophobic amino acids and a basic amino acid is essential for their activity [85] Plactin increases U937 cell-mediated fibrin degradation, which depends on the presence of plasma The profibrinolytic action of one
of the promising compounds, plactin D, has been demonstrated in animal experiments [85]
The action of plactin involves an increase in cellular u-PA activity [85] In this mechanism, the presence of plasma is an absolute requirement The plasma depen-dency is characterized in detail by Harada et al [86], because plasminogen alone cannot substitute for plasma, and the presence of a cofactor for the plactin action is suggested On cultured U937 cells, most of the u-PA molecules exist in the zymogen form,
scu-PA Upon treatment with plactin in the presence of plasma, scu-PA converts to the two-chain form Thus, plactin, in combination with a plasma cofactor, aids proteolytic activation of cellular scu-PA It is interest-ing that malformin A1 (Fig 1), which belongs to another family of cyclopentapeptides, has plasma-dependent activity to promote cellular fibrinolytic activity [87] Although the structural features of mal-formin partially resemble that of plactin, the mecha-nisms involved in their actions are quite different The malformin action does not involve the increase in cellular u-PA activity [87]
Using plactin-affinity gels, Harada et al [86] identi-fied prothrombin as a candidate for a cofactor from plasma The actions of plactin and prothrombin that lead to the activation of scu-PA are explained as follows: (a) plactin binds to prothrombin, alters its conformational status and therefore modulates prothrombin activation by factor Xa; (b) the conse-quence of the modulation under the conditions of the assay for cellular fibrinolytic activity is the promotion
of prothrombin activation; (c) the resulting thrombin can cleave scu-PA at Arg156–Phe157 (two residues
Trang 8proximal to the activation cleavage site, Lys158–
Ile159) to form an inactive two-chain u-PA species;
and (d) the tcu-PA derivative, in turn, is processed
to active tcu-PA by dipeptidyl peptidase I-like activity
of U937 cells, possibly through the removal of
Phe157–Lys158 from the newly formed N-terminus
(Fig 5)
The plactin-modulation of prothrombin activation
leads to different outcomes depending on the form of
the catalyst factor Xa [86] Plactin inhibits
prothrom-bin activation by factor Xa associated with acidic
phospholipid membranes, especially by the
prothrom-binase complex, which accounts for the physiological
coagulation reaction By contrast, plactin enhances
prothrombin activation by membrane-free Xa,
result-ing in increased formation of a-thrombin The
activa-tion of prothrombin is conformaactiva-tionally regulated
The specificity of prothrombinase for prothrombin is
mediated by exosites, which are physically separated
from the catalytic site It has been postulated that
sub-strate recognition by prothrombinase involves a
two-step mechanism with an initial docking of prothrombin
to the exosites, followed by a conformational change
to engage the Xa catalytic site [88] The
plactin-medi-ated dual modulation of prothrombin activation may
be related to the alteration of prothrombin
conforma-tion induced by the agent
Modulator of the activation of plasma
hyaluronan-binding protein
Plasma hyaluronan-binding protein activation
Plasma hyaluronan-binding protein (PHBP;
alterna-tively designated factor VII activating protease) is a
protease that is implicated in both the coagulation and
fibrinolytic systems, because the enzyme catalyzes the activation of factor VII and scu-PA [89,90] It is sug-gested that PHBP plays a role in the regulation of inflammation [91], vascular function [92], neointima formation [93], liver fibrosis [94,95] and atherosclerosis [92,96] PHBP exists in plasma as a single-chain zymo-gen form (pro-PHBP) at a concentration of 170 nm Pro-PHBP consists of 537 amino acids which form the following domains: an N-terminal region, three EGF domains, a kringle domain and a protease domain (Fig 2) [97] The pro-PHBP activation occurs via cleavage at Arg290–Ile291 No physiologically relevant protease that can activate pro-PHBP has been found Alternatively, pro-PHBP can be activated autoproteo-lytically Negatively charged molecules such as heparin and RNA accelerate pro-PHBP autoactivation [98– 101], possibly by serving as a scaffold for the accumu-lation of pro-PHBP, whereas pro-PHBP activation is observed only after hepatic injury, partial hepatectomy [102] or inflammation [103] Thus, pro-PHBP activa-tion may be a highly regulated process and a particular mechanism should be involved in pathophysiological pro-PHBP activation
Polyamines: promotion of pro-PHBP autoactivation complex formation Yamamichi et al [104] searched for inflammation-asso-ciated factors that promote pro-PHBP activation and identified polyamines as potential candidates The polyamines, for example, putrescine, spermidine and spermine, are cationic small molecules that accumulate
in cells undergoing rapid growth and play a role in the regulation of proliferation, differentiation and pro-grammed cell death [105,106] Spermidine markedly enhances intermolecular association of pro-PHBP to form the ‘autoactivation complex’ [104] The impor-tance of the complex formation is supported by the result that a ‘pro-PHBP decoy’, with its active site Ser486 replaced by Ala (S486A), efficiently inhibits the autoactivation The experiments aided by a series of domain-deletion mutants prepared based on the S486A mutant show that: (a) the mutant lacking the third EGF domain (DE3) cannot form the autoactivation complex; (b) heparin, which binds the third EGF domain, inhibits the complex formation; (c) N-terminal region binds to the mutant lacking N-terminal region (DN) and this binding is inhibited by heparin; and (d) spermidine binds to pro-PHBP but not to the DN mutant Thus, the N-terminal region participates in the formation of the pro-PHBP autoactivation complex, and this function is regulated by spermidine (Fig 6) [104]
R
S 1
156
P
S 1
scu-PA (inactive) Thrombin-cleaved
tcu-PA derivative (inactive)
tcu-PA (active)
α-Thrombin
F
Plactin
Prothrombin
Xa
DPP-I-like peptidase
P
R
156
R
P
156
157
I
Fig 5 Prothrombin-mediated pathway to cellular scu-PA activation
promoted by plactin The scu-PA molecule is shown schematically
as in Fig 2 The amino acids involved in proteolytic cleavages are
given in white circles DPP-I, dipeptidyl peptidase I.
Trang 9Carminic acid: specific inhibition of
polyamine-mediated pro-PHBP autoactivation
On the basis of the specific effects of polyamines,
Nishimura et al screened natural sources for an
inhi-bitor of spermidine-induced pro-PHBP activation [107]
and identified several small molecules including
carmi-nic acid [104], an anthraquinone derived from the
cochineal insect Carminic acid inhibits
spermidine-promoted pro-PHBP autoactivation selectively, and
does not affect the autoactivation in the absence of
spermidine or that induced by negatively charged
mol-ecules such as heparin or RNA It also has no effect
on the catalytic activity of the active form of PHBP
This specific effect is due to the inhibition of
autoacti-vation complex formation (Fig 6) Carminic acid may
modulate the polyamine-dependent N-terminal region
function, because the agent inhibits binding between
the N-terminal region and DN only in combination
with spermidine [104] The features of carminic acid,
as well as of polyamines, conform to the idea of the
zymogen modulator
Conclusions and perspectives
The activation of zymogens, particularly those in the
coagulation and fibrinolytic systems, are regulated by
fine mechanisms programmed in their molecules The
small molecules described here act by utilizing or
mod-ulating such embedded mechanisms and do not affect
the catalytic activity of the mature enzymes These
fea-tures discriminate zymogen modulators from inhibitors
or activators that simply act on mature enzymes
Zymogen activation is an allosteric process, and the
zymogen modulators are allosteric effectors acting
dur-ing zymogen activation Selective inhibitors or
antago-nists⁄ agonists have been used as a pharmacologically
powerful means to treat a variety of diseases Zymogen
modulators will contribute to the development of novel
classes of drugs, as their actions are an ideal
on-demand system, which operates where and when the
physiological system is prompted to work, depending
on the physiological supply of the enzyme that acti-vates the zymogen
Acknowledgements
We would like to thank the laboratory staff for their contribution to the studies of zymogen activation mod-ulators, Eriko Suzuki for critical reading of the manu-script and Takashi Tonozuka for construction of the image of kringle 5
References
1 Mann KG, Jenny RJ & Krishnaswamy S (1988) Cofactor proteins in the assembly and expression of blood clotting enzyme complexes Annu Rev Biochem 57, 915–965
2 Rijken DC & Lijnen HR (2009) New insights into the molecular mechanisms of the fibrinolytic system
J Thromb Haemost 7, 4–13
3 Khan AR & James MN (1998) Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes Protein Sci 7, 815–836
4 Hedstrom L (2002) Serine protease mechanism and specificity Chem Rev 102, 4501–4524
5 Tharp AC, Laha M, Panizzi P, Thompson MW, Fuentes-Prior P & Bock PE (2009) Plasminogen substrate recognition by the
kringle 5 of the substrate J Biol Chem 284, 19511– 19521
6 Aneja R, Datt M, Singh B, Kumar S & Sahni G (2009) Identification of a new exosite involved in catalytic turnover by the streptokinase–plasmin activator complex during human plasminogen activation J Biol Chem 284, 32642–32650
7 Panizzi P, Friedrich R, Fuentes-Prior P, Kroh HK, Briggs J, Tans G, Bode W & Bock PE (2006) Novel fluorescent prothrombin analogs as probes of staphylocoagulase–prothrombin interactions J Biol Chem 281, 1169–1178
8 Kroh HK, Panizzi P & Bock PE (2009) Von Willebrand factor-binding protein is a hysteretic conformational activator of prothrombin Proc Natl Acad Sci USA 106, 7786–7791
9 Kolev K & Machovich R (2003) Molecular and cellular modulation of fibrinolysis Thromb Haemost 89, 610–621
10 Lund LR, Green KA, Stoop AA, Ploug M, Almholt
K, Lilla J, Nielsen BS, Christensen IJ, Craik CS, Werb
Z et al (2006) Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice EMBO J 25, 2686–2697
Autoactivation complex
E1
E2
P
E1
E2
P
E1 E2 E3
E3
P
E1 E2 E3
E3
P Carminic
acid
PHBP Polyamine
Pro-PHBP
E3
K
Fig 6 A model of the modulation of pro-PHBP autoactivation by
polyamine and carminic acid The pro-PHBP molecule is shown as
in Fig 2 The schematic conformation shown is speculative.
Trang 1011 Danø K, Behrendt N, Høyer-Hansen G, Johnsen M,
Lund LR, Ploug M & Romer J (2005) Plasminogen
activation and cancer Thromb Haemost 93, 676–681
12 Castellino FJ & Ploplis VA (2005) Structure and
Haemost 93, 647–654
13 Forsgren M, Raden B, Israelsson M, Larsson K &
Heden L-O (1987) Molecular cloning and
characterization of a full-length cDNA clone for
human plasminogen FEBS Lett 213, 254–260
14 Tordai H, Banyai L & Patthy L (1999) The PAN
module: the N-terminal domains of plasminogen and
hepatocyte growth factor are homologous with the
apple domains of the prekallikrein family and with a
novel domain found in numerous nematode proteins
FEBS Lett 461, 63–67
15 Cockell CS, Marshall JM, Dawson KM,
Cederholm-Williams SA & Ponting CP (1998) Evidence that the
conformation of unliganded human plasminogen is
maintained via an intramolecular interaction between
the lysine-binding site of kringle 5 and the N-terminal
peptide Biochem J 333, 99–105
16 An SS, Carren˜o C, Marti DN, Schaller J, Alberico F &
Llinas M (1998) Lysine-50 is a likely site for anchoring
the plasminogen N-terminal peptide to lysine-binding
kringles Protein Sci 7, 1960–1969
17 Violand BN, Sodetz JM & Castellino FJ (1975) The
effect of epsilon-aminocaproic acid on the gross
conformation of plasminogen and plasmin Arch
Biochem Biophys 170, 300–305
18 Christensen U & Molgaard L (1991) Stopped-flow
fluorescence kinetic studies of Glu-plasminogen
Conformational changes triggered by AH-site ligand
binding FEBS Lett 278, 204–206
19 Nesheim ME, Fredenburgh JC & Larsen GR (1990)
The dissociation constants and stoichiometries of the
interactions of Lys-plasminogen and chloromethyl
ketone derivatives of tissue plasminogen activator and
the variant DFEIX with intact fibrin J Biol Chem 265,
21541–21548
20 Hajjar KA & Nacman L (1988) Endothelial
cell-mediated conversion of Glu-plasminogen to
Lys-plasminogen Further evidence for assembly of the
fibrinolytic system on the endothelial cell surface
J Clin Invest 82, 1769–1778
21 Wygrecka M, Marsh LM, Morty RE, Henneke I,
Guenther A, Lohmeyer J, Markart P & Preissner KT
(2009) Enolase-1 promotes plasminogen-mediated
recruitment of monocytes to the acutely inflamed lung
Blood 113, 5588–5598
22 Kawao N, Nagai N, Ishida C, Okada K, Okumoto K,
Suzuki Y, Umemura K, Ueshima S & Matsuo O
(2010) Plasminogen is essential for granulation tissue
formation during the recovery process after liver injury
in mice J Thromb Haemost 8, 1555–1566
23 Andronicos NM, Chen EI, Baik N, Bai H, Parmer CM, Kiosses WB, Kamps MP, Yates JR III, Parmer RJ & Miles LA (2010) Proteomics-based discovery of a novel, structurally unique, and developmentally regulated
surface plasminogen activation Blood 115, 1319–1330
24 O’Connell PA, Surette AP, Liwski RS, Svenningsson P
& Waisman DM (2010) S100A10 regulates plasminogen-dependent macrophage invasion Blood, doi: 10.1182/blood-2010-01-264754
25 Fredenburgh JC & Nesheim ME (1992) Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis
in vitro J Biol Chem 267, 26150–26156
26 Violand BN & Castellino FJ (1976) Mechanism of the urokinase-catalyzed activation of human plasminogen
J Biol Chem 251, 3906–3912
27 Marshall JM, Brown AJ & Ponting CP (1994) Conformational studies of human plasminogen and plasminogen fragments: evidence for a novel third conformation of plasminogen Biochemistry 33, 3599–3606
28 Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A & Castellino FJ (1998) Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen Biochemistry 37, 3258–3271
29 Battistel MD, Grishaev A, An SS, Castellino FJ & Llinas M (2009) Solution structure and functional characterization of human plasminogen kringle 5 Biochemistry 48, 10208–10219
30 Christensen U (1984) The AH-site of plasminogen and two C-terminal fragments A weak lysine-binding site preferring ligands not carrying a free carboxylate function Biochem J 223, 413–421
31 Urano T, Chibber BA & Castellino FJ (1987) The reciprocal effects of epsilon-aminohexanoic acid and chloride ion on the activation of human [Glu1]plasmi-nogen by human urokinase Proc Natl Acad Sci USA
84, 4031–4034
32 Urano T, Sator de Serrano V, Chibber BA &
Castellino FJ (1987) The control of the urokinase-catalyzed activation of human glutamic acid 1-plasminogen by positive and negative effectors J Biol Chem 262, 15959–15964
33 Wiles KG, Panizzi P, Kroh HK & Bock PE (2010) Skizzle is a novel plasminogen and plasmin binding protein from Streptococcus agalactiae that targets proteins of human fibrinolysis to promote plasmin generation J Biol Chem 285, 21153–21164
34 Michaeli A, Finci-Yeheskel Z, Dishon S, Linke RP, Levin M & Urieli-Shoval S (2008) Serum amyloid A enhances plasminogen activation: implication for a role
in colon cancer Biochem Biophys Res Commun 368, 368–373